Salud financiera de hoja de balance de ADMA Biologics
Salud financiera controles de criterios 6/6
ADMA Biologics tiene un patrimonio de accionistas total de $231.9M y una deuda total de $101.3M, lo que sitúa su ratio deuda-patrimonio en 43.7%. Sus activos y pasivos totales son $390.6M y $158.7M respectivamente. El BAIT de ADMA Biologics es de $117.7M, por lo que su ratio de cobertura de intereses es de 7.8. Tiene efectivo e inversiones a corto plazo que ascienden a $86.7M.
Información clave
43.7%
Ratio deuda-patrimonio
US$101.33m
Deuda
| Ratio de cobertura de intereses | 7.8x |
| Efectivo | US$86.71m |
| Patrimonio | US$231.89m |
| Total pasivo | US$158.73m |
| Activos totales | US$390.62m |
Actualizaciones recientes sobre salud financiera
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($318.2M) de ADMA superan a sus pasivos a corto plazo ($44.9M).
Pasivo a largo plazo: Los activos a corto plazo de ADMA ($318.2M) superan a sus pasivos a largo plazo ($113.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (6.3%) de ADMA se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de ADMA ha pasado de 229.1% a 43.7% en los últimos 5 años.
Cobertura de la deuda: La deuda de ADMA está bien cubierta por el flujo de caja operativo (84.9%).
Cobertura de intereses: Los pagos de intereses de la deuda de ADMA están bien cubiertos por el BAIT (7.8x cobertura).